Latest news with #CSI
Daily Mail
3 days ago
- Entertainment
- Daily Mail
Brad Pitt's home terrorized by thieves who scaled fence and smashed windows to break in
Brad Pitt 's California home has been terrorized by thieves after they scaled a fence and smashed windows to break in amid his current press tour for his new film, F1. Three suspects allegedly broke into the star's home in Los Feliz, Los Angeles on Wednesday at around 10:30pm, the Los Angeles Police Department said. The 61-year-old actor was not home at the time and it is unclear if his girlfriend Ines de Ramon was inside when the thieves struck. Investigators told NBC News that the thieves climbed over Pitt's front fence and ransacked the home, stealing an unknown amount of property. It comes after a string of celebrities have had their Los Angeles-area homes broken into in recent years. Crime scene investigators descended on the actor's Los Angeles mansion on Thursday. Pictures obtained by captured the CSI team trawling the home for evidence in the hours after the incident. One source told the LA Times that the criminals smashed a window before entering the home and made 'a real mess' of it. They allegedly stole Pitt's possessions, and overturned his furniture as though they were 'looking for what they could take of value,' a source told the publication. An insider said Pitt's belongings were tossed all over the floor during the crime. One masked officer wearing blue gloves and carrying a toolkit was seen at the property as investigators tried to look for clues. Plain clothing officers also came back and forth from the home as the investigation continued. This includes Pitt's ex-girlfriend Jennifer Aniston, as well as couples Nicole Kidman and Keith Urban and Tom Hanks and Rita Wilson. It is unclear if the string of burglaries are connected. Pitt has been busy promoting his new film, F1, and was most recently spotted with his girlfriend at the London premiere earlier this week. F1 was made in collaboration with Formula One's governing body, the FIA, with seven-time world champion Lewis Hamilton being one of the producers. In the film, Pitt plays troubled race car driver Sonny Hayes, who races against rookie rival Joshua Pearce (Damson Idris) as they battle it out o various Grand Prix race courses around the world. The movie's red carpet premiere was the first time the couple have taken their relationship super public.
West Australian
4 days ago
- Business
- West Australian
Not selling MinRes mining services unit says Mike Grey, with Onslow staying in the black a white-hot focus
The 'crown jewel' of Mineral Resources is not for sale, according to the man that oversees the division, because keeping it could help the company's flagship mine turn a decent profit even if iron ore crashes below $US60 per tonne. MinRes mining services chief executive Mike Grey shot down speculation a big chunk of the business unit he oversees could be flogged off to ease the company's swelling debt burden. The speculation emerged following a note published by Morgan Stanley this week. 'There's no truth to it all, no truth,' Mr Grey told The West Australian. Director of strategy, Tim Picton, chimed in to say the division – called CSI Mining Services – was the company's 'crown jewel'. 'You don't sell the crown jewel and mining services is the heart of our business and what makes us competitive against the majors,' Mr Picton said. 'We've got no plans to sell any of our assets, except the (mothballed) Yilgarn (iron ore complex).' CSI is the mining services provider at MinRes' majority-owned iron ore and lithium mines, and is also contracted to other operations run by the likes of BHP, Rio Tinto and Gina Rinehart. MinRes' $3.5 billion Onslow Iron project is arguably CSI's most important gig. Onslow is the only mine in the MinRes stable that can generate the meaningful sums of cash required to pay down the company's $5.8 billion debt pile. MinRes reckons its 57 per cent stake in Onslow can bring in annual earnings before interest, tax, depreciation and amortisation of $727 million when the iron ore spot price is $US90/t. The steelmaking commodity is currently at about $US92/t with Australia's big four banks broadly pencilling in the price to fall to $US80/t by the end of the year. MinRes predicts Onslow's break-even price is $US57/t. Mr Picton said this estimate does not include the money raked in from mining services at Onslow, which would push the break-even price 'down a material amount'. But all the estimates are contingent on Onslow Iron running smoothly, and so far, there have been numerous bumps along the road. The biggest bump has been the performance of its haul road that links the Kens Bore mine to the Port of Ashburton. MinRes is spending $230 million to fix and upgrade the road following cyclonic weather earlier this year and a spate of truck rollovers. The company struggled to attract drivers to transport ore along the road and recently had to lower its driver experience requirements while boosting the pay on offer. Mr Grey said those hiring struggles are now behind MinRes. 'The labour side has really stabilised across the supply chain recently which is really good,' he said. 'We're at our peak now with (truck) drivers.' MinRes plans to roll out autonomous trucks with no drivers in the cabs during the latter half of next year.
Morocco World
19-06-2025
- Business
- Morocco World
Morocco, US Sign New Container Security Initiative Agreement
Marrakech – Morocco and the United States took a further step forward in their customs cooperation with the signing of a new bilateral Container Security Initiative (CSI) arrangement in Rabat on Tuesday. The agreement aims to enhance cargo security and facilitate the high volume of trade between the two countries. 'Today's signing marks not just the expansion of the CSI program, but the strengthening of a partnership rooted in trust, innovation, and a shared responsibility to protect our global community,' said Donald Conroy, Executive Director of the Office of Field Operations International Operations and Advisory Directorate at US Customs and Border Protection (CBP) during the event. The CSI arrangement will expand law enforcement efforts between Washington and Rabat, enhancing targeting and information sharing to identify and counter customs violations and other threats in the cargo environment. The agreement covers the vital ports of Casablanca and Tanger Med, with Casablanca being a crucial commercial hub and Tanger Med being the largest port in Africa and the Mediterranean Sea. The signing ceremony was also attended by Abdellatif Amrani, General Director of the Customs and Excise Administration in Morocco and Aimee Cutrona, US Chargé d'Affaires in Rabat. Senior officials from Morocco Customs (ADII), CBP, and the US Embassy were also present. Amrani stressed Morocco's commitment to balancing security and trade facilitation, stating, 'With this accession, we reaffirm our commitment to harmonizing security with the seamless flow of trade, thereby consolidating Tanger Med's standing as a secure, world-class maritime hub.' The CSI program, launched in 2002 following the 9/11 attacks, is a proactive and strategic security initiative that aims to identify and inspect high-risk maritime cargo containers at foreign ports before they are shipped to the United States. The program partners with foreign customs administrations and other agencies to pre-screen, evaluate, and target potential threats using advanced technology, intelligence, and shared protocols. The new accord is based on the 2013 Customs Mutual Assistance Agreement between the two sides of the Atlantic, which provides the legal framework for the exchange of information and evidence to assist in the enforcement, prevention, detection, and investigation of customs offenses. With this new agreement, Tanger Med joins a network of CSI-certified Mediterranean ports, including Algeciras (Spain), Marseille (France), and Gioia Tauro (Italy). Chargé d'Affaires Cutrona shed light on the significance of the agreement, stating, 'Today's signing of the new Container Security Initiative arrangement between the United States and the Kingdom of Morocco marks a significant milestone in our enduring partnership.' 'This agreement not only strengthens our collaborative efforts to secure global supply chains but also underscores our shared commitment to innovation, security, and economic prosperity,' she added. With the extension of the CSI network, the Moroccan and US customs administrations are reinforcing their efforts in targeting and predictive analysis of high-risk cargo before shipment, contributing to the effective fight against threats and ensuring the protection of consumers and citizens of both nations. Read also: Morocco's El Jadida to Host First International Port Ecosystem Salon in 2026 Tags: cargo handling MoroccoMorocco US Relations
Business Upturn
18-06-2025
- Health
- Business Upturn
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
Presentation underscores unique potential for atrioventricular interval modulation ('AVIM') therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction and progression to heart failure with preserved ejection fraction ('HFpEF') Hypertensive heart disease represents over 7.7 million U.S. patients, the same population with hypertension and elevated cardiovascular risk cited in the recent FDA Breakthrough Device Designation ('BDD') for AVIM therapy NEW HOPE, Pa., June 18, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, 'Orchestra BioMed' or the 'Company'), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the presentation of key clinical insights into the role of AVIM therapy for the treatment of high-risk hypertension at the Congenital, Structural, and Valvular Heart Disease Interventions ('CSI') 2025 Meeting. The data highlight AVIM therapy's unique potential to address hypertensive heart disease, a significant and under-recognized cardiovascular syndrome that affects a growing segment of the aging hypertension population. The talk, 'Atrioventricular Interval Modulation (AVIM) Therapy for Hypertension and HFpEF,' will be delivered by Daniel Burkhoff, M.D., Ph.D., Director of Heart Failure, Hemodynamics and Mechanical Circulatory Support Research at Cardiovascular Research Foundation and clinical advisor to Orchestra BioMed. Dr. Burkhoff will spotlight the clinical utility of AVIM therapy as a novel, device-based approach to blood pressure management designed specifically for patients with hypertensive heart disease. This population has increased risk for major adverse cardiac events and currently lacks sufficient therapeutic options. The presentation will take place on June 18, 2025, at 3:33pm CEST / 9:33am ET as part of the ' Interventions for Chronic Heart Failure ' session. Dr. Burkhoff commented, 'Hypertensive heart disease is not a singular diagnosis, but a high-risk cardiovascular syndrome driven by longstanding, uncontrolled high blood pressure which significantly increases the likelihood of adverse clinical outcomes such as stroke, myocardial infarction, diastolic dysfunction and progression to heart failure. The data I will review at CSI explore how AVIM therapy may offer a unique treatment specifically catered to this group of patients leveraging a mechanism of action designed to reduce cardiac preload and modulate autonomic nervous system responses to reduce blood pressure and improve cardiovascular function. This represents a potential paradigm shift in how we approach blood pressure management using tailored interventions designed to directly impact the complex pathophysiology of high-risk hypertension.' The presentation will cover: The clinical burden and therapeutic gaps in managing patients with high-risk hypertension and increased risk of heart failure; in managing patients with high-risk hypertension and increased risk of heart failure; The growing body of clinical and mechanistic evidence demonstrating AVIM therapy's potential to lower blood pressure and improve cardiac function; and demonstrating AVIM therapy's potential to lower blood pressure and improve cardiac function; and Details on the BACKBEAT global pivotal study, currently enrolling patients with uncontrolled hypertension who are indicated for a dual-chamber pacemaker. The study is being conducted in collaboration with Medtronic, the global leader in cardiac pacing therapy. 'AVIM therapy was purpose-built to address the complex and underserved needs of patients with hypertensive heart disease, a subgroup often overlooked by conventional therapy,' said Avi Fischer, M.D., Senior Vice President of Medical Affairs and Innovation at Orchestra BioMed. 'As a programmable, pacemaker-integrated solution, AVIM therapy has the potential to fit seamlessly into existing electrophysiology practices while opening the door to better outcomes in a large, underserved population. Dr. Burkhoff's presentation at CSI Frankfurt further reinforces the growing clinical interest in AVIM therapy and highlights the significant opportunity to transform care of hypertensive heart disease, especially given our recently granted BDD status, which applies directly to this patient profile.' About Orchestra BioMed Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed's lead product candidate is AVIM therapy for the treatment of hypertension, the leading risk factor for death worldwide. Orchestra BioMed is also developing Virtue SAB for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. The Company has received four Breakthrough Device Designations from the U.S. FDA across these two core programs, reflecting the significant potential of its technologies to address high unmet needs in cardiovascular care. For further information about Orchestra BioMed, please visit , and follow us on LinkedIn . References to Websites and Social Media Platforms References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release. About AVIM Therapy AVIM therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot study, showed that patients treated with AVIM therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal study will further evaluate the safety and efficacy of AVIM therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker. AVIM therapy has been granted Breakthrough Device Designation by the FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk. Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the enrollment, implementation and design of the Company's planned and ongoing pivotal trials, realizing the clinical and commercial value of the Company's product candidates, the potential safety and efficacy of the Company's product candidates, and the ability of the Company's partnerships to accelerate clinical development. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company's commercial product candidates and ongoing regulation of the Company's product candidates, if approved; the timing of, and the Company's ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading 'Item 1A. Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 31, 2025 and the risk factor discussed under the heading 'Item 1A. Risk Factors' in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, which was filed with the SEC on May 12, 2025. The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law. Investor ContactSilas NewcombOrchestra BioMed [email protected]
Yahoo
18-06-2025
- Yahoo
Decatur man arrested after allegedly shooting mother in buttocks
Jun. 18—A Decatur man was charged with second-degree domestic violence last week after shooting his mother in the buttocks with a pistol, according to a Morgan County sheriff's investigator's affidavit filed Monday. According to the affidavit, deputies responded to a shooting call on June 10 at 424 Aday Road N.W. The caller told deputies that her son, 38-year-old Matthew Ryan Martinez, had shot her. Martinez's mother had not seen him in three months and he "randomly" showed up at her residence. "(The caller) advised that when Matthew came in her residence, she gave him a hug and Matthew did not show much affection and just patted her on the back," the affidavit said. The affidavit said Martinez's mother then went to sit on her couch and told him he could sit as well, but instead, he just stood by the front door and was not acting normally. He became hostile when his mother asked about his eBay business and began mumbling incoherently. After looking back at her TV, she heard Martinez say something like "Bye, Mom," and she heard gunshots shortly after. "(The caller) advised that she felt a burning pain in her buttocks and realized that Matthew had shot her," the affidavit said. "She said that as she was getting up, she heard Matthew leaving her property in his truck at a high rate of speed." Morgan County 911 then issued a BOLO (be on the lookout) for Martinez and his vehicle, a white Nissan Titan four-door truck. The affidavit said Decatur police officers were able to stop Martinez in his truck a short time later. As they were searching the truck, officers located two handguns on the passenger side of the vehicle. "CSI recovered three spent 9mm casings at the scene," the affidavit said. Martinez was booked into Morgan County Jail at approximately 9:36 p.m. and released Monday after posting a $75,000 bond, according to court documents. — or 256-340-2442.
